SELLAS loses arbitration against 3D Medicines; cash $138.3M as of June 30

SELLAS Life Sciences Group, Inc.

Arbitration claims dismissed; company ordered to pay ~$1.0M in legal fees.
3D Medicines to continue GPS development; $191.5M in potential milestones remain, including $13.0M disputed.
Preliminary unaudited cash and equivalents $138.3M as of June 30, 2026.

Featured in Daily 8-K Digest

Selected #8 for 2026-07-27. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.